ICH Stability Testing

ICH stability testing evaluates how a pharmaceutical product’s quality changes over time when exposed to environmental factors such as temperature, humidity, and light. These studies are performed according to International Council for Harmonisation (ICH) guidelines and are required to support regulatory submissions. The results establish the product’s shelf life, recommended storage conditions, and overall stability throughout its intended lifecycle.

The duration of a stability study depends on the type of testing being performed. Accelerated studies typically run for 6 months, while long-term stability studies usually last 12–36 months to confirm the product’s shelf life. In many cases, accelerated data is used early in development, while long-term studies continue to generate data for regulatory submissions and ongoing product monitoring.

Real-time stability testing evaluates a product under normal storage conditions over the intended shelf life. This provides the most accurate data on how the product performs during actual storage.
Accelerated stability testing exposes the product to elevated temperature and humidity to speed up chemical and physical degradation. This allows manufacturers to predict potential stability issues more quickly during product development.
Accelerated studies help generate early data, but real-time studies are ultimately required to confirm shelf life.

Stability testing typically begins as soon as the final formulation and packaging configuration are established. Testing should be performed using product manufactured with the same process and packaging system intended for commercial production.
Starting stability studies early helps ensure sufficient data is available to support regulatory submissions and shelf-life claims.

ICH defines a significant change as a result that indicates the product may no longer meet its approved specifications under accelerated conditions. Examples may include:
• A 5% or greater decrease in assay from the initial value
• Any degradation product exceeding its specification limit
• Failure to meet dissolution or physical specifications
• Significant changes in appearance or physical properties
If a significant change occurs during accelerated testing, an intermediate stability study (30°C / 65% RH) may be required to further evaluate product stability.

ICH guidelines generally require a minimum of three primary batches for stability testing. These batches should be manufactured using the same process and equipment intended for commercial production.
At least two of the batches should be pilot-scale or production-scale, and the third may sometimes be smaller depending on development stage. Testing multiple batches ensures that stability results are representative of normal manufacturing variability.

Yes. ICH guidelines recommend that stability testing be conducted using the same container-closure system intended for commercial distribution.
Packaging can significantly affect product stability by influencing exposure to moisture or oxygen. Evaluating the product in its final packaging ensures that the stability data accurately reflects real-world storage conditions.

Q1A – Stability Testing of New Drug Substances and Products - Outlines requirements for long term / Intermediate / accelerated testing of drug products
Q1C – Stability Testing for New Dosage Forms - Identical logic of Q1A just on new dosage amounts of already documented substances
Q1F – Stability testing for Climatic Zones 3 and 4 - Guidance on Stability requirements for higher temperature and humidity regions